<SEC-DOCUMENT>0000950123-21-010419.txt : 20210812
<SEC-HEADER>0000950123-21-010419.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812074608
ACCESSION NUMBER:		0000950123-21-010419
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210812
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		211165518

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d340778d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of August 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;12, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d340778dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g340778ex99_1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Reports Positive Interim Analysis from Phase 2/3 Study of
its <FONT STYLE="white-space:nowrap">GM-CSF</FONT> Antibody Plonmarlimab (TJM2) to Treat Patients with Severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Interim analysis showed positive preliminary results for maintaining patients without mechanical ventilation
and reducing the mortality rate, with shortened time to recovery and hospitalization duration</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>A reduction in key <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and chemokines
critically involved in cytokine release syndrome (CRS) was observed in patients treated with plonmarlimab compared to placebo </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Plonmarlimab treatment was well tolerated with no significant safety concerns in patients with severe <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">I-Mab</FONT> plans to continue advancing the study in the U.S. and begins to
explore other <FONT STYLE="white-space:nowrap">CRS-related</FONT> opportunities </I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China and GAITHERSBURG, MD. &#150;
August</B><B></B><B>&nbsp;11, 2021 &#150;</B> <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel
biologics, today announced positive interim data from its U.S. phase 2/3 study (<U>NCT04341116</U>) of plonmarlimab (also known as TJM2 or TJ003234) for the treatment of cytokine release syndrome (CRS) in patients with severe <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> Plonmarlimab was discovered and developed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> to target human granulocyte-macrophage colony-stimulating factor <FONT STYLE="white-space:nowrap">(GM-CSF),</FONT>
a cytokine that plays a critical role in acute and chronic inflammation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> virus <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(SARS-CoV-2),</FONT></FONT> particularly the Delta variant, is known to cause a pathologic surge of circulating inflammatory cytokines termed cytokine release syndrome (CRS) or cytokine
storm, which is responsible for complications and higher mortality associated with the disease. Plonmarlimab plays a critical therapeutic role in CRS through the inhibition of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> that acts at the upstream
of the pathologic inflammatory cascade and is expected to be more efficacious in preventing and treating CRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very excited about the data
and plonmarlimab could be a very promising treatment for hospitalized patients with <FONT STYLE="white-space:nowrap">COVID-19,&#148;</FONT> said Deepa Gotur, MD, associate professor of clinical medicine at Houston Methodist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ongoing U.S. phase 2/3 study is one of the first double-blind, placebo-controlled, randomized studies to evaluate the therapeutic role of <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> antibody in severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. The study aimed to determine the safety, efficacy and effects on cytokine levels following a single dose of 6&nbsp;mg/kg of
plonmarlimab or placebo in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current interim analysis showed positive
preliminary results in patients who were mechanical ventilation free (MVF) at baseline (N=91). Plonmarlimab treatment resulted in a higher MVF rate (83.6% vs 76.7%) by day 30, lower mortality rate (4.9% vs 13.3%) by day 30, higher recovery rates
(68.9% vs 56.7% at day 14 and 80.3% vs 70.0% at day 30), as well as reduced time to recovery and hospitalization duration, as compared to placebo. The magnitudes of the clinical improvements are comparable to those observed with lenzilumab in a
similar patient population.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Biomarker results were consistent with the observed clinical outcome and indicated patients treated with plonmarlimab had a reduction in plasma levels of <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and chemokines critically involved in CRS, including TARC, IP10, GCSF, IL10, IL6, MCP1, IL1RA, TNF-alpha but not interferon-gamma. A transient increase in Neutrophil to Lymphocyte Ratio
(NLR) that is commonly associated with disease exacerbation was only observed in placebo. Plonmarlimab was well tolerated in all patients with no significant safety concerns. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1.full.pdf </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai,
China<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>www.i-mabbiopharma.com</U></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g340778ex99_1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Plonmarlimab has shown very promising results from the interim data analysis in our phase 2/3 trial,
and we intend to continue advancing the study in the U.S. at this critical juncture of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and continue exploring other clinical opportunities associated with CRS,&#148; said Dr.&nbsp;Joan
Shen, CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Plonmarlimab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plonmarlimab (or TJM2) is an
internally discovered neutralizing antibody against human <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as RA <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> can polarize macrophages into the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype and is known to induce an inflammatory cascade involving other
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines such as tumor-necrosis factor (TNF), <FONT STYLE="white-space:nowrap">interleukin-1</FONT> <FONT STYLE="white-space:nowrap">(IL-1),</FONT>
<FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IL-12,</FONT> and <FONT STYLE="white-space:nowrap">IL-23.</FONT> It is evident that <FONT STYLE="white-space:nowrap">GM-CSF</FONT> plays a crucial role in the
pathogenesis and disease progression of multiple autoimmune conditions.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plonmarlimab specifically binds to human
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> with high affinity and can block <FONT STYLE="white-space:nowrap">GM-CSF</FONT> from binding to its receptor, thereby preventing downstream signalling and target cell activation. As a result, it can
effectively inhibit inflammatory responses mediated by macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development, and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of
immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients around the world through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline of more than 10
clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s <FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies through internal R&amp;D and
global partnerships. The Company is on track to transition from a clinical-stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&amp;D capabilities, world-class GMP manufacturing facilities, and
commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in Beijing, Shanghai, Hangzhou, Hong Kong, and Maryland, United States. For more information, please visit
<U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U>, and <U>WeChat</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai,
China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>www.i-mabbiopharma.com</U></P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g340778ex99_1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding data from the plonmarlimab phase 2/3 trial, the potential implications of clinical data for patients, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> advancement of, and anticipated clinical development,
regulatory milestones, and commercialization of plonmarlimab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing
of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial
success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
reliance on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain
additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial
and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well
as discussions of potential risks, uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on
information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information, please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jielun Zhu,
Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6057 8000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng, Chief Communications
Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E-mail: <FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6057 5709 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Piacente Group, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emilie Wu </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> emilie@thepiacentegroup.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: + 86 21 6039 8363 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai,
China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>www.i-mabbiopharma.com</U></P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g340778ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g340778ex99_1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MAKQCJFG20RG3B"IN&0JA*G*G/3H3^=&(J0E34F[,5",J=1QZ&G\0O#\OBAK
MV5U"@MA(&WJYSNVXQM4^AKEHXVC1O>[]$V:5Z;J6L9WB#P5X>B\-S/IEA.=1
M51LVNX)/?ASR/8#-71Q\9SLY67FK&=2A!0]U:F[\,M/U+3_"VS4$>(/,SQ12
M##*I [=N0QQ[U>(E&4[Q-<-&48:G:5SG2<E\3'9/AYJQ7J1&OX&10?YUT89?
MO4<V*=J,CPS1W-M.L@&1C!'M7O1T/FZBNK'J7@K2(M5U W,R[K>W ;&.&8]
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.. % !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
